AN2 Therapeutics (ANTX) Change in Cash (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Change in Cash for 6 consecutive years, with $33.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 2555.78% year-over-year to $33.5 million; the TTM figure through Mar 2026 stood at $33.5 million (up 811.6% YoY), while the FY2025 annual figure was -$1.4 million, down 124.72% from the prior year.
• Change in Cash grew to $33.5 million in Q1 2026 per ANTX's latest filing, from $1.9 million in the prior quarter.
• Across five years, Change in Cash topped out at $70.4 million in Q1 2022 and bottomed at -$41.9 million in Q2 2022.
• Historically, Change in Cash has averaged $2.4 million across 5 years, with a median of -$510000.0 in 2023.
• Annual changes were most pronounced in 2023 — Change in Cash slumped 971.95% — and 2026, when it soared 2555.78%.
• AN2 Therapeutics' Change in Cash stood at -$1.6 million in 2022, then plunged by 971.95% to -$17.0 million in 2023, then climbed by 28.38% to -$12.2 million in 2024, then jumped by 115.95% to $1.9 million in 2025, then soared by 1630.96% to $33.5 million in 2026.
• Business Quant data shows ANTX's Change in Cash at $33.5 million in Q1 2026, $1.9 million in Q4 2025, and -$217000.0 in Q3 2025.